A Clinical and Imaging Registry of Transcatheter Aortic Valve Implantation Using JenaValve System/ J-Valve System for Patients With Pure Aortic Regurgitation

Last updated: June 13, 2025
Sponsor: Prince of Wales Hospital, Shatin, Hong Kong
Overall Status: Active - Recruiting

Phase

N/A

Condition

Heart Valve Disease

Treatment

JenaValve

J-Valve

Clinical Study ID

NCT07021612
2025.079
  • Ages > 18
  • All Genders

Study Summary

Aortic regurgitation (AR) is not uncommon. Transcatheter aortic valve implantation (TAVI) for treating pure aortic regurgitation is a potential future treatment option for pure AR especially in patients having high risk for open heart surgery.

TAVI using dedicated device for pure AR has a different anchor mechanism to TAVI for aortic stenosis (AS). AR patientsalso have different cardiac flow pattern, aortic root pathology and left ventricular remodeling pattern compared to AS patients. Subclinical leaflet thrombosis has been described in AS patient receiving TAVI, which will affect the durability and antithrombotic regime. Follow-up imaging for dedicated TAVI device in AR patient is limited.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. receiving transcatheter aortic valve implantation (TAVI) (using Jenavalve/J-Valve)in PWH

  2. with severe symptomatic AR (NYHA III-IV) despite optimal medical therapy

  3. Deemed high risk for aortic valve surgery determined by a multidisciplinary heartteam (including cardiologists, cardiac surgeons and cardiac anesthetists)

  4. Capable of providing informed consent

Exclusion

Exclusion Criteria:

  1. Evidence of intracardiac mass, thrombus or vegetation

  2. Anatomical structures precluding proper device deployment or device vascular access,evaluated by echo or CT

  3. Sepsis or active endocarditis within 3 months, or infections requiring antibiotictherapy within 2 weeks prior to the planned procedure

  4. Subjects currently participating in another clinical trial of an investigationaldrug or device that has not yet completed its primary endpoint.

  5. Chronic Kidney Disease with eGFR <30 ml/min/1.73m2.

  6. Cardiogenic shock or other hemodynamic instability requiring inotropic support orventricular assist device

  7. Contraindicated for CT or MRI assessment

Study Design

Total Participants: 30
Treatment Group(s): 2
Primary Treatment: JenaValve
Phase:
Study Start date:
April 01, 2025
Estimated Completion Date:
September 30, 2028

Connect with a study center

  • Prince of Wales Hospital

    Hong Kong, Shatin 0000
    Hong Kong

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.